Email this article 
Post a Comment Vitamin D deficiency in children with cystic fibrosis:is there a link with the microflora of the lower respiratory tract, the frequency of hospitalizations and the volumeof antibiotic therapy?
- Authors: Pashkevich A.A.1, Nachinkina T.A.2, Ushatskaia O.A.2, Dorofeikov V.V.3, Orlov A.V.4, Kostik M.M.1, Jelenina L.A.1
-
Affiliations:
- St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
- City Children's Hospital Saint Olga
- Lesgaft National State University of Physical Education, Sport and Health
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 9, No 6 (2018)
- Pages: 5-12
- Section: Articles
- URL: https://journals.rcsi.science/pediatr/article/view/11218
- DOI: https://doi.org/10.17816/PED965-12
- ID: 11218
Cite item
Abstract
Background. Cystic fibrosis (CF) – a hereditary disease which is characterized by a chronic infection and inflammation in airways and leads to the progressing of the lung damage and an early disability.
The aim of our study to evaluate the relationship between vitamin D deficiency and degree of the contamination of the lower airways (LA) by the main pathogens and requirement in intravenous (IV) antibacterial therapy and hospital admission duration.
Materials and methods. The study included 92 children with CF aged from 0 to 17 years. During the research (18 months) the serum 25(OH)D levels were evaluated trice. Vitamin D3 titration dosage was made according the 25(OH)D level and data about treatment compliance collected. According to the register of patients the number of flares and days of antibacterial therapy for 3 periods was counted: during 1 year before inclusion in the study (2016), for 2017 (during treatment) and in 2018. Statistical analysis was carried out with Statistica 10.0 software.
Results. From 92 people, only 66 were compliant and in 38/66 the normal level of 25(OH)D was reached. At children with initially normal level of vitamin D the requirement in IV antibacterial therapy within the first year of observation decreased. In patients who had normal 25(OH)D serum level (>30 ng/ml) we observed decreased number of in-patient department admission and decreased frequency of gram-negative bacteria of LA detection.
Conclusions. The maintenance of normal blood vitamin D level was a perspective therapeutic strategy in CF patients which may reduce the frequency of a chronic infection and as a result, the requirements in hospital admission and IV antibacterial therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Aleksandr A. Pashkevich
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: pashkevich_aa@live.ru
Post-Graduate Student, Department of Hospital Pediatrics
Russian Federation, Saint PetersburgTatjana A. Nachinkina
City Children's Hospital Saint Olga
Email: db4@zdrav.spb.ru
Chief Pediatrician
Russian Federation, Saint PetersburgOksana A. Ushatskaia
City Children's Hospital Saint Olga
Email: ushatskaia@icloud.com
Pediatrician
Russian Federation, Saint PetersburgVladimir V. Dorofeikov
Lesgaft National State University of Physical Education, Sport and Health
Email: vdorofeykov@yandex.ru
MD, PhD, Dr Med Sci, Associate Professor, Head, Department of Biochemistry
Russian Federation, Saint PetersburgAleksandr V. Orlov
North-Western State Medical University named after I.I. Mechnikov
Email: orlovcf@yandex.ru
MD, PhD, Associate Professor, Department of Pediatrics and Neonatology
Russian Federation, Saint PetersburgMichail M. Kostik
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: kost-mikhail@yandex.ru
MD, PhD, Dr Med Sci, Associate Professor, Department of Hospital Pediatrics
Russian Federation, Saint PetersburgLudmila A. Jelenina
St. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Email: jelenina@mail.ru
MD, PhD, Dr Med Sci, Professor, Head, Department of Pediatrics, Ftiziopulmonology and Endocrinology, Faculty of Postgraduate Education
Russian Federation, Saint PetersburgReferences
- Баранова И.А., Кондратьева Е.И., Красовский С.А. Остеопороз при муковисцидозе: меры профилактики и терапевтические возможности // Пульмонология. - 2017. - Т. 27. - № 4. - С. 537-545. [Baranova IA, Kondrat’eva EI, Krasovskiy SA. Osteoporosis in cystic fibrosis patients: prevention and therapeutic opportunities. Russian Pulmonology. 2017;27(4):537-545. (In Russ.)]. doi: 10.18093/0869-0189-2017-27-4-537-545.
- Регистр больных муковисцидозом в Российской Федерации. 2016 год / Под ред. С.А. Красовского, А.В. Черняка, А.Ю. Воронковой, и др. - М.: МЕДПРАКТИКА-М, 2018. [Registr bol’nykh mukovistsidozom v Rossiyskoy Federatsii. 2016. Ed. by S.A. Krasovskiy, A.V. Chernyak, A.Y. Voronkova, et al. Moscow: MEDPRAKTIKA-M; 2018. (In Russ.)]
- Остеопороз: руководство для врачей / Под ред. О.М. Лесняк. - М.: ГЭОТАР-Медиа, 2016. [Osteoporoz: rukovodsto dlya vrachey. Ed. by O.M. Lesnyak. Moscow: GEOTAR-Media; 2016. (In Russ.)]
- Строев Ю.И., Соболевская П.А., Чурилов Л.П., Утехин В.И. Роль гипокальциемии и витамина D3 в патогенезе фобий при хроническом аутоиммунном тиреоидите Хасимото // Педиатр. - 2017. - Т. 8. - № 4. - С. 39-42. [Stroev YI, Sobolevskaya PA, Churilov LP, Utehin VJ. The role of hypocalcemia and vitamin D3 in pathogenesis of phobias in chronic autoimmune Hashimoto’s thyroiditis. Pediatrician (St. Petersburg). 2017;8(4):39-42. (In Russ.)]. doi: 10.17816/PED8439-42.
- Rbht.nhs.uk [Internet]. Care of children with cystic fibrosis 2017 contents [cited 2018 Dec 11]. Available from: https://www.rbht.nhs.uk/care-children-cystic-fibrosis-2017-contents.
- Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest. 2005;128(6):3792-3798. doi: 10.1378/chest.128.6.3792.
- De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett. 2005;27(18):1337-1347. doi: 10.1007/s10529-005-0936-5.
- Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-642. doi: 10.1056/NEJM199409083311003.
- Herscovitch K, Dauletbaev N, Lands LC. Vitamin D as an anti-microbial and anti-inflammatory therapy for Cystic Fibrosis. Paediatr Respir Rev. 2014;15(2):154-62. doi: 10.1016/j.prrv.2013.11.002.
- Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi: 10.1056/NEJMra070553.
- Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S-1086S. doi: 10.1093/ajcn/87.4.1080S.
- Hopkinson NS, Li KW, Kehoe A, et al. Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease. Am J Clin Nutr. 2008;87(2):385-390. doi: 10.1093/ajcn/87.2.385.
- Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34. doi: 10.1016/s1569-1993(02)00141-8.
- Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003;89(5):922-932. doi: 10.1002/jcb.10580.
- McPhail GL, Chini B, Siracusa C, et al. Vitamin D insufficiency is associated with pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2015;14: S112. doi: 10.1016/s1569-1993(15)30387-8.
- Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23-30. doi: 10.1056/NEJM199901073400104.
- Sexauer WP, Hadeh A, Ohman-Strickland PA, et al. Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. J Cyst Fibros. 2015;14(4):497-506. doi: 10.1016/j.jcf.2014.12.006.
- Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014;13 Suppl 1: S23-42. doi: 10.1016/j.jcf.2014.03.010.
- Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97(4):1082-1093. doi: 10.1210/jc.2011-3050.
- Thursfield RM, Naderi K, Leaver N, et al. Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency. J Cyst Fibros. 2018;17(5):657-65. doi: 10.1016/j.jcf.2018.02.011.
- Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006;116(1):146-155. doi: 10.1172/JCI21759.
- Zolin A, Bossi A, Cirilli N, et al. Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. Int J Environ Res Public Health. 2018;15(9). doi: 10.3390/ijerph15092020.
